Drugs / AMG 650
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06084416 | Apr 2024 → Mar 2026 overdue | fallopian tube cancer, ovarian serous adenocarcinoma, primary peritoneal carcinoma | Volastra Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04293094 | Mar 2020 → Oct 2022 | neoplasm | Volastra Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 650 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04293094 ↗ |
| Known as | Sovilnesib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06084416 ↗ |
| Action | Inhibit | “KIF18A Inhibitor” NCT06084416 ↗ |
| Modality | Small molecule | — CHEMBL5084301 ↗ |
| Route | Oral | “AMG 650 administered orally as a tablet.” NCT04293094 ↗ |
| Target | KIF18A | “KIF18A Inhibitor” NCT06084416 ↗ |